Skip to main content

Fangzhou Reports Sustained Revenue and Profit Growth as AI-Powered Chronic Care Strategy Gains Momentum

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

HONG KONG, Aug. 27, 2026 (GLOBE NEWSWIRE) — Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, announced its interim results for the six months ended June 30, 2026, reporting revenue of RMB 1.8245 billion, a 22.2% year-on-year increase, and adjusted net profit of RMB 18.7 million, up 6.4% from the same period last year. The results reflect the Company’s continued execution of its “AI + chronic care” strategy amid favorable policy momentum under China’s 15th Five-Year Plan.

Fangzhou’s user and physician networks also expanded during the period. Cumulative registered users exceeded 59.8 million, while average monthly active users increased 23.1% to 14.7 million. Registered physicians reached 282,000. The Company’s supply chain included more than 1,800 suppliers and 1,000 pharmaceutical companies, with prescription medicines accounting for 83.1% of GMV.

Fangzhou also expanded industry partnerships, signing strategic agreements with pharmaceutical companies including Youcare Pharmaceutical and Tenry Pharma and extending its services into innovative therapies and specialty care. Meanwhile, the Company completed agreements and system integration for medical insurance services across Guangdong Province, expanding access to online follow-up consultations, prescription renewals and medication purchases for insured patients.

AI remained a key driver of Fangzhou’s growth strategy. Powered by its proprietary “XingShi” Large Language Model (“XS LLM”), the Company expanded AI applications across patient services, physician support and internal operations. For physicians, Fangzhou integrated AI pre-consultation, clinical support and academic-assistance capabilities to reduce repetitive administrative tasks and improve post-consultation patient management. Internally, AI tools were deployed across service fulfillment, inventory management and logistics to improve operating and supply-chain efficiency.

Fangzhou believes these initiatives are instrumental to shifting chronic disease management from episodic interactions toward continuous, full-cycle healthcare services, while allowing limited physician resources to serve a broader patient population.

For the second half of 2026, Fangzhou said it will position itself as a “full-lifecycle personal health service partner,” building an integrated ecosystem serving patients, physicians and pharmaceutical companies. The strategy aims to provide patients with trusted long-term health services, equip physicians with efficient digital collaboration tools and help pharmaceutical partners accelerate commercial applications.

Fangzhou plans to continue upgrading its large-model and AI-agent capabilities, scale the deployment of AI applications, and deepen partnerships with pharmaceutical and technology companies, thereby aligning its corporate growth with the broader goals of the Healthy China 2030 initiative.

About Fangzhou Inc.

Fangzhou Inc. (HKEX: 06086) is China’s leading online chronic disease management platform, serving 59.8 million registered users and 282,000 physicians (as of June 30, 2026). The Company specializes in delivering tailored medical care and AI‑enabled precision medicine solutions. For more information, visit https://investors.jianke.com.

Media Contact

For further inquiries or interview requests, please contact:

Xingwei Zhao
Director of Public Relations
Email: pr@jianke.com

Disclaimer: This press release contains forward‑looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.